(Total Views: 334)
Posted On: 05/22/2017 2:03:58 PM
Post# of 72447
Re: someconcerns #34022
Farai response to Biohedge:
Quote:
faraifarai Monday, 05/22/17 11:09:24 AM
Re: BioHedge post# 182788
Post # of 182846
Yep--I was simply taking what I view is the lowest/worst case sell per indication category to demonstrate how easy it is to get into the many billions with where the pipeline currently is. Crazy to think about how limitless the potential seems with Brilacidin. It seems to work all over the skin, in every hole it enters (pardon the crudeness) and without any/nasty side effects. If i had any of these ailments, i'd be asking for the B straight away. I think FDA Breakthrough designation for oral mucositis is not a matter of if but when. No preventative exists and their interim data is absurdly good. FDA probably waiting for more patients for statistical relevance, and guessing that number is probably double the interim...so july for breakthrough? that's a catalyst that could add a fast $100-$200M in market cap.
(1)
(0)
